{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:07:23Z","timestamp":1790615243754,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K10474"],"award-info":[{"award-number":["21K10474"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H03355"],"award-info":[{"award-number":["22H03355"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K10451"],"award-info":[{"award-number":["21K10451"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nara Medical University Center for Diversity and Inclusion"},{"name":"the Ministry of Health, Labor and Welfare","award":["Hypothalamo-hypophyseal Disorders and Endocrine Syndrome with Sexual Differentiation and Maturation grant"],"award-info":[{"award-number":["Hypothalamo-hypophyseal Disorders and Endocrine Syndrome with Sexual Differentiation and Maturation grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although antithyroid drug (ATD)-induced agranulocytosis is a significant concern, its risks associated with long-term use and re-administration are not fully elucidated. Therefore, we performed this study to determine the incidence of ATD-induced leukopenia and G-CSF administration using administrative claims database. Retrospective cohort study. This study was performed using the DeSC Japanese administrative claims database. A total of 12,491 patients with newly diagnosed Graves\u2019 disease (GD) who received methimazole or propylthiouracil between April 2014, and February 2021 among 3.44 million patients in the database were included in the study. We measured the six-year incidence of leukopenia and granulocyte colony-stimulating factor (G-CSF) administration. The incidence of leukopenia and G-CSF administration was 1.34% (168 patients) and 0.30% (38 patients), respectively. Leukopenia had a dose-dependent and biphasic incidence. The incidence of leukopenia and G-CSF administration was 37.2 (0.7%) and 8.0 (0.2%) per 1000 person-years during the first 72\u00a0days of ATD initiation, whereas it was 3.1 and 0.7 per 1000 person-years during the subsequent 6\u00a0years, respectively. The incidence of both outcomes was comparable between first administration and re-administration of ATD. The incidence of ATD-induced leukopenia and G-CSF administration was high in the first 72\u00a0days, with a reduced risk for at least 6\u00a0years thereafter. The incidence was similar between first administration and re-administration. ATD, a standard therapy, is often administered for a long period; therefore, our findings can guide the treatment of GD.<\/jats:p>","DOI":"10.1038\/s41598-023-46307-5","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T18:02:06Z","timestamp":1699380126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antithyroid drug-induced leukopenia and G-CSF administration: a long-term cohort study"],"prefix":"10.1038","volume":"13","author":[{"given":"Fumika","family":"Kamitani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1956-3925","authenticated-orcid":false,"given":"Yuichi","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Kurematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadanori","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Myojin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"46307_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000490384","volume":"7","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly, G. J. et al. 2018 European Thyroid Association guideline for the management of Graves\u2019 hyperthyroidism. Eur. Thyroid J. 7, 167\u2013186. https:\/\/doi.org\/10.1159\/000490384 (2018).","journal-title":"Eur. Thyroid J."},{"key":"46307_CR2","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1089\/thy.2019.0180","volume":"29","author":"F Azizi","year":"2019","unstructured":"Azizi, F. et al. Increased remission rates after long-term methimazole therapy in patients with Graves\u2019 disease: Results of a randomized clinical trial. Thyroid 29, 1192\u20131200. https:\/\/doi.org\/10.1089\/thy.2019.0180 (2019).","journal-title":"Thyroid"},{"key":"46307_CR3","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross, D. S. et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26, 1343\u20131421. https:\/\/doi.org\/10.1089\/thy.2016.0229 (2016).","journal-title":"Thyroid"},{"key":"46307_CR4","unstructured":"Guideline for the Tratment of Graves\u2019 Disease in Japan. Japan Thyroid Association, 2019. https:perperwww.japanthyroid.jpperdoctorperguidelineperindex.html."},{"key":"46307_CR5","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1001\/jama.2015.16535","volume":"314","author":"HB Burch","year":"2015","unstructured":"Burch, H. B. & Cooper, D. S. Management of Graves disease: A review. J. Am. Med. Assoc. 314, 2544\u20132554. https:\/\/doi.org\/10.1001\/jama.2015.16535 (2015).","journal-title":"J. Am. Med. Assoc."},{"key":"46307_CR6","doi-asserted-by":"publisher","first-page":"E49","DOI":"10.1210\/jc.2011-2221","volume":"97","author":"N Watanabe","year":"2012","unstructured":"Watanabe, N. et al. Antithyroid drug-induced hematopoietic damage: A retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves\u2019 disease. J. Clin. Endocrinol. Metab. 97, E49\u2013E53. https:\/\/doi.org\/10.1210\/jc.2011-2221 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46307_CR7","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1210\/jc.2013-2569","volume":"98","author":"H Nakamura","year":"2013","unstructured":"Nakamura, H., Miyauchi, A., Miyawaki, N. & Imagawa, J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J. Clin. Endocrinol. Metab. 98, 4776\u20134783. https:\/\/doi.org\/10.1210\/jc.2013-2569 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"46307_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1089\/thy.2015.0439","volume":"26","author":"J Yang","year":"2016","unstructured":"Yang, J. et al. Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: A retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid 26(5), 627\u2013633 (2016).","journal-title":"Thyroid"},{"key":"46307_CR9","first-page":"A2430","volume":"155","author":"M Stellingwerf","year":"2011","unstructured":"Stellingwerf, M., Jellema, W. T., Eland, I. A. & Wakelkamp, I. M. Agranulocytosis\/granulocytopenia after long-term use of thiamazole. Ned Tijdschr Geneeskd 155, A2430 (2011).","journal-title":"Ned Tijdschr Geneeskd"},{"key":"46307_CR10","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.4158\/EP11339.CR","volume":"18","author":"P Mutharasan","year":"2012","unstructured":"Mutharasan, P., Oatis, W., Kwaan, H. & Molitch, M. Delayed anithyroid drug-induced agranulocytosis. Endocrine Pract. 18, e69\u2013e72. https:\/\/doi.org\/10.4158\/EP11339.CR (2012).","journal-title":"Endocrine Pract."},{"key":"46307_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/qjmed\/94.8.423","volume":"94","author":"E Andres","year":"2001","unstructured":"Andres, E. et al. Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis. QJM Int. J. Med. 94, 423\u2013428. https:\/\/doi.org\/10.1093\/qjmed\/94.8.423 (2001).","journal-title":"QJM Int. J. Med."},{"key":"46307_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1089\/thy.2005.15.292","volume":"15","author":"J Tajiri","year":"2005","unstructured":"Tajiri, J. & Noguchi, S. Antithyroid drug-induced agranulocytosis: How has granulocyte colony-stimulating factor changed therapy?. Thyroid 15, 292\u2013297. https:\/\/doi.org\/10.1089\/thy.2005.15.292 (2005).","journal-title":"Thyroid"},{"key":"46307_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/thy.1999.9.29","volume":"9","author":"S Fukata","year":"1999","unstructured":"Fukata, S., Kuma, K. & Sugawara, M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: A prospective study. Thyroid 9, 29\u201331. https:\/\/doi.org\/10.1089\/thy.1999.9.29 (1999).","journal-title":"Thyroid"},{"key":"46307_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3389\/fendo.2019.00789","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Granulocyte-colony-stimulating factor effectively shortens recovery duration in anti-thyroid-drug-induced agranulocytosis: A systematic review and meta-analysis. Front. Endocrinol. (Lausanne) 10, 789. https:\/\/doi.org\/10.3389\/fendo.2019.00789 (2019).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"46307_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.31662\/jmaj.2021-0189","volume":"5","author":"A Okada","year":"2022","unstructured":"Okada, A. & Yasunaga, H. Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J. 5, 190\u2013198. https:\/\/doi.org\/10.31662\/jmaj.2021-0189 (2022).","journal-title":"JMA J."},{"issue":"15","key":"46307_CR16","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1056\/NEJMc0809750","volume":"360","author":"SA Rivkees","year":"2009","unstructured":"Rivkees, S. A. & Mattison, D. R. Ending propylthiouracil-induced liver failure in children. N. Engl. J. Med. 360(15), 1574\u20131575. https:\/\/doi.org\/10.1056\/NEJMc0809750 (2009).","journal-title":"N. Engl. J. Med."},{"key":"46307_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00210-019-01774-4","volume":"393","author":"K Sebastian","year":"2020","unstructured":"Sebastian, K., Rene, P., Inke, R. K., Roland, L. & Markus, S. Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data. Naunyn-Schmiedeberg\u2019s Arch. Pharmacol. 393, 681\u2013690 (2020).","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"46307_CR18","first-page":"928","volume":"77","author":"E Roti","year":"1993","unstructured":"Roti, E. et al. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves\u2019 hyperthyroidosm. J. Clin. Endocrinol. Metab. 77, 928\u2013932 (1993).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46307_CR19","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/0006-2952(79)90692-0","volume":"28","author":"DC Lam","year":"1979","unstructured":"Lam, D. C. & Lindsay, R. H. Accumulation of 2-[14C]propylthiouracil in human polymorphonuclear leukocytes. Biochem. Pharmacol. 28, 2289\u20132296. https:\/\/doi.org\/10.1016\/0006-2952(79)90692-0 (1979).","journal-title":"Biochem. Pharmacol."},{"key":"46307_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1365-2265.1989.tb01424.x","volume":"30","author":"H Tamai","year":"1989","unstructured":"Tamai, H. et al. Methimazole-induced agranulocytosis in Japanese patients with Graves\u2019 disease. Clin. Endocrinol. 30, 525\u2013530. https:\/\/doi.org\/10.1111\/j.1365-2265.1989.tb01424.x (1989).","journal-title":"Clin. Endocrinol."},{"key":"46307_CR21","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1210\/jc.2012-2802","volume":"97","author":"HB Burch","year":"2012","unstructured":"Burch, H. B., Burman, K. D. & Cooper, D. S. A 2011 survey of clinical practice patterns in the management of Graves\u2019 disease. J. Clin. Endocrinol. Metab. 97, 4549\u20134558. https:\/\/doi.org\/10.1210\/jc.2012-2802 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46307_CR22","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1210\/jc.2003-030185","volume":"88","author":"DS Cooper","year":"2003","unstructured":"Cooper, D. S. Antithyroid drugs in the management of patients with Graves\u2019 disease: An evidence-based approach to therapeutic controversies. J. Clin. Endocrinol. Metab. 88, 3474\u20133481. https:\/\/doi.org\/10.1210\/jc.2003-030185 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46307_CR23","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1089\/thy.2019.0814","volume":"30","author":"F Azizi","year":"2020","unstructured":"Azizi, F. Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience. Thyroid 30, 1451\u20131457. https:\/\/doi.org\/10.1089\/thy.2019.0814 (2020).","journal-title":"Thyroid"},{"key":"46307_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1365-2265.2004.02135.x","volume":"61","author":"SH Pearce","year":"2004","unstructured":"Pearce, S. H. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin. Endocrinol. 61, 589\u2013594. https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02135.x (2004).","journal-title":"Clin. Endocrinol."},{"key":"46307_CR25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/105072504323150787","volume":"14","author":"J Tajiri","year":"2004","unstructured":"Tajiri, J. & Noguchi, S. Antithyroid drug-induced agranulocytosis: Special reference to normal white blood cell count agranulocytosis. Thyroid 14, 459\u2013462. https:\/\/doi.org\/10.1089\/105072504323150787 (2004).","journal-title":"Thyroid"},{"key":"46307_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/thy.2008.0364","volume":"19","author":"K Takata","year":"2009","unstructured":"Takata, K. et al. Methimazole-induced agranulocytosis in patients with Graves\u2019 disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19, 559\u2013563. https:\/\/doi.org\/10.1089\/thy.2008.0364 (2009).","journal-title":"Thyroid"},{"key":"46307_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40268-017-0172-1","volume":"17","author":"N Vicente","year":"2017","unstructured":"Vicente, N., Cardoso, L., Barros, L. & Carrilho, F. Antithyroid drug-induced agranulocytosis: State of the art on diagnosis and management. Drugs R&D 17, 91\u201396. https:\/\/doi.org\/10.1007\/s40268-017-0172-1 (2017).","journal-title":"Drugs R&D"},{"key":"46307_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1517\/17425255.2015.985649","volume":"11","author":"A Johnston","year":"2015","unstructured":"Johnston, A. & Uetrecht, J. Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Expert Opin. Drug Metab. Toxicol. 11, 243\u2013257. https:\/\/doi.org\/10.1517\/17425255.2015.985649 (2015).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"46307_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.7326\/0003-4819-124-5-199603010-00005","volume":"124","author":"SH Kaplan","year":"1996","unstructured":"Kaplan, S. H., Greenfield, S., Gandek, B., Rogers, W. H. & Ware, J. E. Jr. Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease. Ann. Intern. Med. 124, 490\u2013494. https:\/\/doi.org\/10.7326\/0003-4819-124-5-199603010-00005 (1996).","journal-title":"Ann. Intern. Med."},{"key":"46307_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2141.1986.tb04130.x","volume":"64","author":"WE Fibbe","year":"1986","unstructured":"Fibbe, W. E. et al. Agranulocytosis induced by propylthiouracil: Evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. Br. J. Haematol. 64, 363\u2013373. https:\/\/doi.org\/10.1111\/j.1365-2141.1986.tb04130.x (1986).","journal-title":"Br. J. Haematol."},{"key":"46307_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1600-0609.1988.tb00803.x","volume":"40","author":"D Douer","year":"1988","unstructured":"Douer, D. & Eisenstein, Z. Methimazole-induced agranulocytosis: Growth inhibition of myeloid progenitor cells by the patient\u2019s serum. Eur. J. Haematol. 40, 91\u201394. https:\/\/doi.org\/10.1111\/j.1600-0609.1988.tb00803.x (1988).","journal-title":"Eur. J. Haematol."},{"key":"46307_CR32","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1089\/thy.2013.0476","volume":"24","author":"S Kobayashi","year":"2014","unstructured":"Kobayashi, S. et al. Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment. Thyroid 24, 796\u2013801. https:\/\/doi.org\/10.1089\/thy.2013.0476 (2014).","journal-title":"Thyroid"},{"issue":"5","key":"46307_CR33","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1111\/ajco.12983","volume":"14","author":"YD Chu","year":"2018","unstructured":"Chu, Y. D. et al. A novel thyroid function index associated with opposite therapeutic outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib. Asia Pac. J. Clin. Oncol. 14(5), e341\u2013e351 (2018).","journal-title":"Asia Pac. J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46307-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46307-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46307-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T18:07:46Z","timestamp":1699380466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46307-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["46307"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-46307-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"19 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FK received speaker fees from Dainippon Sumitomo, Sanofi, and Kyowa Kirin. YN received consultation fees from Novo Nordisk. SO received speaker fees from Ono; Mitsubishi Tanabe; Dainippon Sumitomo; Eli Lilly, Japan; Takeda; AstraZeneca; Novartis Pharmaceuticals; Novo Nordisk; Mochida Pharmaceutical; Kyowa Kirin; and Terumo. YT received consultant fees from Novo Nordisk, Otsuka, and Recordati and speaker fees from Novo Nordisk, Sumitomo Dainippon, Eli Lilly, Ono, Novartis, Nippon Boehringer Ingelheim, AstraZeneca, and Kyowa Kirin. The other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19336"}}